Capabilities by Region: Continental Europe
Greenhill has considerable advisory experience in Continental Europe. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout Continental Europe. Greenhill established its presence in Continental Europe in November 2000 with the opening of a Frankfurt office. Greenhill further expanded its presence with the opening of a Madrid office in 2017 and a Paris office in 2020.
For more information on Greenhill’s advisory practice in Continental Europe and our capabilities in the region, please contact President David Wyles in our London office, Managing Director Philip Meyer Horn in our Frankfurt office, Javier Gonzalez in our Madrid Office or Amélie Négrier-Oyarzabal in our Paris office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
NAC 33 & NAC 34, subsidiaries of Nordic Aviation Capital
Advised Azorra Aviation, a leading commercial aircraft lessor backed by Oaktree Capital Management, on the chapter 11 restructuring and related investment in NAC 33 & 34, two exiting subsidiaries of Nordic Aviation Capital
Siemens’ Commercial Vehicles Bus & Truck Electric Propulsion Business
Advised Meritor, Inc, a global supplier of automobile components from drivetrain to brake systems, on its acquisition of Siemens’ Commercial Vehicles Bus & Truck Electric Propulsion Business
Netrics Digital Infrastructure
Advising NorthC, the largest regional data center provider in the Netherlands, on their agreement to acquire the data centers and connectivity services of Netrics in Switzerland
Tekfor Group
Advised American Axle & Manufacturing Holdings, Inc., a leading manufacturer of driveline and drivetrain systems and related components, on the acquisition of Tekfor Group, a leading specialist for mission-critical high-performance components, modules and fasteners
Acacia Pharma Group plc
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise